Dynamics of propranolol dosing schedules

Area of Science:

• Pharmacokinetics and Pharmacodynamics
• Cardiovascular Pharmacology

Background:

• Propranolol is a beta-adrenergic receptor antagonist used in various cardiovascular conditions.
• Optimal dosing regimens for sustained therapeutic effects and patient adherence are crucial.

Purpose of the Study:

• To compare the pharmacokinetic and pharmacodynamic profiles of propranolol administered twice daily versus three times daily.
• To evaluate the impact of different dosing frequencies on plasma propranolol levels and beta-1 blockade efficacy.

Main Methods:

• A double-blind, randomized, double-crossover study involving 27 healthy male subjects.
• Assessment of kinetic and dynamic data, including plasma propranolol concentrations (maximum concentration, AUC0-24, 0-hr values) and beta-1 blockade (reduction in exercise tachycardia).

Main Results:

• Twice-daily dosing resulted in higher maximum concentration, AUC0-24, and 0-hr plasma propranolol values compared to three-times-daily dosing.
• The degree of beta-1 blockade, measured by reduction in exercise tachycardia, was comparable between the two dosing regimens at trough concentrations.
• Both dosing schedules demonstrated well-sustained 24-hour beta-blockade.

Conclusions:

• Twice-daily propranolol administration may be favored over three-times-daily dosing when beta-1 blockade is a therapeutic goal, due to higher plasma levels.
• Despite differences in plasma levels, both dosing frequencies provide comparable and sustained 24-hour beta-blockade, suggesting interchangeability for therapeutic purposes.